50
Participants
Start Date
March 31, 2025
Primary Completion Date
November 30, 2026
Study Completion Date
November 30, 2030
GS1191-0445 injection
A single intravenous administration of GS1191-0445 injection at a dose of 3E12 vg/kg
NOT_YET_RECRUITING
Peking Union Medical College Hospital, Beijing
NOT_YET_RECRUITING
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing
NOT_YET_RECRUITING
Anhui Provincial Hospital, Hefei
RECRUITING
Central Hospital Affiliated to Shandong First Medical University, Jinan
RECRUITING
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin
NOT_YET_RECRUITING
Jiangxi Provincial People's Hospital, Nanchang
NOT_YET_RECRUITING
Xiangya Hospital of Central South University, Changsha
NOT_YET_RECRUITING
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
NOT_YET_RECRUITING
Nanfang Hospital Southern Medical University, Guangzhou
NOT_YET_RECRUITING
The second Affiliated Hospital of Kunming Medical University, Kunming
NOT_YET_RECRUITING
First Hospital of Lanzhou University, Lanzhou
NOT_YET_RECRUITING
North China University of Science and Technology Affiliated Hospital, Tangshan
Lead Sponsor
Gritgen Therapeutics Co., Ltd.
INDUSTRY